Evidence map›Paper›PMID 28806398›Full record

ArticleOncogene2017

Lysine-52 stabilizes the MYC oncoprotein through an SCF

J De Melo, S S Kim, C Lourenco, L Z Penn

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

J De MeloPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0001-6519-4879
S S KimPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
C LourencoPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
L Z PennPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
University Health Network · CA

Funding

CIHR MOP275788
6 · The paper itself

Abstract

The oncogenic transcription factor c-MYC (MYC) is deregulated and often overexpressed in more than 50% of cancers. MYC deregulation is associated with poor prognosis and aggressive disease, suggesting that the development of therapeutic inhibitors targeting MYC would markedly impact patient outcome. MYC is highly regulated, with a protein and mRNA half-life of ~30 min. The most extensively studied pathway regulating MYC protein stability involves ubiquitylation and proteasomal degradation mediated by the E3-ligase, SCF

Indexed as

UbiquitinationAnimalsArginineCell LineCell Line, TumorDoublecortin ProteinF-Box-WD Repeat-Containing Protein 7Half-LifeHCT116 CellsHEK293 CellsHumansImmunoblottingLysineMutation, MissenseProtein StabilityProto-Oncogene Proteins c-mycArginineDcx protein, ratDoublecortin ProteinF-Box-WD Repeat-Containing Protein 7LysineProto-Oncogene Proteins c-myc

Identifiers

PMID28806398
OpenAlexW2750212851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.